<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03730038</url>
  </required_header>
  <id_info>
    <org_study_id>4-2018-0794</org_study_id>
    <nct_id>NCT03730038</nct_id>
  </id_info>
  <brief_title>Effects of Pitavastatin Treatments on the Plasma Lgi3 Level in the Patients With Dyslipidemia</brief_title>
  <official_title>Effects of Pitavastatin Treatments on the Plasma Lgi3 Level in the Patients With Dyslipidemia: A Randomized Crossover Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Leucine-rich glioma inactivated 3(Lgi3) has been postulated to have a pro-inflammatory&#xD;
      adipokine that inter-plays with other adipokines in adipogenesis and metabolic inflammation&#xD;
      according to recent investigations. Thus, in this study, we sought to demonstrate that the&#xD;
      treatment of statin can decrease Lgi3 level along with the decrease of the atherosclerosis to&#xD;
      further evaluate the role of Lgi3 in atherosclerosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who assigned to the pitavastatin treatment first group will be given the&#xD;
      pitavastatin 4 mg qd treatment for 12 weeks after randomization, followed by wash-out period&#xD;
      of 3 weeks and life-style modification treatment for 12 weeks. Similarly, patients who&#xD;
      assigned to the life-style modification treatment first group, will be treated with&#xD;
      life-style modification treatment for 12 weeks after randomization, followed by wash-out&#xD;
      period of 3 weeks and pitavastatin treatment for 12 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 18, 2019</start_date>
  <completion_date type="Actual">February 13, 2020</completion_date>
  <primary_completion_date type="Actual">February 13, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Patients who assigned to the pitavastatin treatment first group will be given the pitavastatin, followed by wash-out period and life-style modification treatment. Patients who assigned to the life-style modification treatment first group, will be treated with life-style modification treatment first, followed by wash-out period and pitavastatin treatment.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Lgi3 level</measure>
    <time_frame>At 12 weeks after intervention</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Pitavastatin treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of pitavastatin 4 mg qd for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Life-style modification</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment of pitavastatin 4 mg qd for 12 weeks</intervention_name>
    <description>Treatment of pitavastatin 4 mg qd for 12 weeks</description>
    <arm_group_label>Pitavastatin treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Life-style modification</intervention_name>
    <description>Nutritional support with the meal less than 65% of carbohydrate, less than 30% of fat. Exercise 3-4 times, 30 min</description>
    <arm_group_label>Life-style modification</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 20-80 years&#xD;
&#xD;
          -  Patients with intermediate or low cardiovascular risks needing the statin treatment&#xD;
&#xD;
          -  Patients with intermediate or low cardiovascular risks treating the statin treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients without signed informed consent&#xD;
&#xD;
          -  Patients with myopathy&#xD;
&#xD;
          -  Pregnant women or women with potential childbearing&#xD;
&#xD;
          -  Patients with diabetes&#xD;
&#xD;
          -  Patients with established coronary artery disease&#xD;
&#xD;
          -  Patients with heart failure&#xD;
&#xD;
          -  Life expectancy less than 1 year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 1, 2018</study_first_submitted>
  <study_first_submitted_qc>November 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2018</study_first_posted>
  <last_update_submitted>October 14, 2020</last_update_submitted>
  <last_update_submitted_qc>October 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dyslipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

